New aspects of diagnosis and therapy of hepatocellular carcinoma. (Q36519032)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

New aspects of diagnosis and therapy of hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Alejandro Forner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Josep M. Llovet

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Hessheimer AJ

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Boix L

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Vilana R

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

English

0 references

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

3848-3856

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.onc.1209548

25 December 2019

exact match

0 references

cites work

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

Local/regional and systemic treatments of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Screening for hepatocellular carcinoma in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Primary liver cancer: worldwide incidence and trends

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Chemoembolization for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Results of the first year of the new liver allocation plan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

1 reference

7 January 2021

Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Resection and liver transplantation for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Management of hepatocellular carcinoma in the waiting list before liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Newer markers for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

The meaning of life expectancy: what is a clinically significant gain?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Prognostic prediction in patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Liver transplantation for hepatocellular carcinoma: the MELD impact.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Alphafetoprotein: an obituary.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Living-donation liver transplantation for hepatocellular carcinoma: time to drop the limitations?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Early hepatocellular carcinoma as an entity with a high rate of surgical cure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Randomized controlled trial of screening for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209548

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1209548

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16799626%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference